[Kerafast] From the Freezer: April 2019 Kerafast E-Newsletter
작성자
abbabio
작성일자
2019-04-09
조회수
331
Engineered Recombinant DNA/RNA Hybrid Antibodies Last year we merged with Absolute Antibody, a company specializing in recombinant antibody technology, and we’re now working together to create recombinant versions of unique lab-made antibodies. In one exciting example, we engineered four new formats of the National Institutes of Health’s DNA/RNA Hybrid [S9.6] Antibody – rabbit IgG, goat IgG, mouse IgG2a and His-tagged mouse Fab antibody fragment – all absolutely defined at the amino acid level to ensure batch-to-batch reproducibility. Learn more here.
Featured Lab Dr. Elizabeth M. Boon Lab, Stony Brook University The Boon lab studies the molecular mechanisms by which bacteria regulate biofilm formation. Their long-term goal is to understand nitric oxide (NO) signaling in bacteria on a molecular and community level, and to employ that knowledge to advance human health. Dr. Boon’s Engineered Diguanylate Cyclase has been available via Kerafast since 2016, and this year she also added the lab’s highly pure Cyclic Diguanosine Monophosphate (c-di-GMP), a second messenger used in signal transduction in bacteria.
Crypto Antibodies in the News Cryptosporidiosis can cause serious infection in both humans and calves, and Dr. Michael Rigg’s lab at the University of Arizona had developed a panel of monoclonal antibodies for detecting the parasite. The university recently announced that the antibodies had become available via Kerafast, in order to advance research toward better Crypto diagnosis and treatment. Read the announcement here, and view the Crypto antibodies in our catalog here.
Saving a Malaria Antibody with Therapeutic Potential A Brown University lab dedicated to developing better malaria treatments had identified a promising anti-malaria antibody, but had to abandon it after the hybridoma stopped expressing. Learn how hybridoma sequencing was used to rescue the antibody in a new case study from our sister company Absolute Antibody. The antibody can now be produced recombinantly and is currently undergoing humanization to move it toward clinical use. Read the full story here.
Our team is in Atlanta this week for the American Association for Cancer Research (AACR) annual meeting! We’re exhibiting along with our Absolute Antibody colleagues in booth #4710. If you’re in town, stop by to learn about our unique 
